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FRACTURE NONUNION ETIOLOGY, DIAGNOSIS, AND TREATMENT: 
CURRENT UNDERSTANDINGS AND APPROACHES 
 
GEORGE BRADLEY REAHL 
 
ABSTRACT 
 
Fracture healing is a carefully orchestrated process that closely resembles embryonic 
skeletal development. In 5-10% of all fractures however this process arrests or is 
impeded, creating a nonunion of bone across the fracture site that severely complicates 
patient recovery at great economic cost. The pathophysiology of this complication 
remains largely unknown, although the disruption of specific cytokine signaling 
pathways, lack of osteogenic cells, vascular disruption, and a suboptimal mechanical 
environment may all contribute. Smoking, diabetes, and the use of NSAIDs have also 
demonstrated associations with nonunion. Diagnosis of a nonunion has also proven 
difficult as radiographic and clinical assessments remain the gold standard but are largely 
subjective. Following a diagnosis, surgical intervention is typically pursued and 
augmented with pharmacologic agents and bone stimulators, although evidence for the 
effectiveness of both remains limited. 
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The future of nonunion understanding and diagnosis are coupled, as current research into 
the complication’s pathophysiology hopes to elucidate biologic markers of bone healing 
potentially disrupted in nonunion and detectable in the serum. The use of these markers 
in addition to the expanded use of validated radiographic scoring present the most 
promising future diagnostic tools. Advanced grafting techniques and compounds as well 
as stronger evidence-based pharmacologic augmentation seek to improve outcomes after 
treatment as well. Overall, this review seeks to provide a comprehensive report of current 
understandings, diagnostics, and treatments for fracture nonunion and the evidence that 
supports them, as well as present current and planned future research aimed at developing 
more efficacious diagnostic and therapeutic modalities.  
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INTRODUCTION 
 
Fracture nonunion is a complex and debilitating complication occurring after the fixation 
of a fractured bone. It is defined broadly by the Food and Drug Administration (FDA) as 
a failure of radiographically determined bony callus bridging between adjacent ends of a 
fracture within nine months of initial injury with an arrest in healing for three consecutive 
months.50  This complication has long been believed to occur in approximately 5% to 
10% of all long bone fractures, although recent studies place this number on the lower 
end of that assessment.73,113 Any bone that has sustained a fracture is at risk of 
progressing to nonunion. However, the incidence of nonunion varies significantly bone to 
bone and is variable dependent on the anatomical location within a specific bone. A 2016 
landmark review by Zura et al has demonstrated such variation through the assessment of 
the long-term outcomes of 309,330 fractures, finding the highest nonunion rates to occur 
in the scaphoid (15.5%), tibia and fibula (14%), and femur (13.9%). The metacarpal and 
radius were determined to have the lowest rates of nonunion, at 1.5% and 2.1% 
respectively.113 Nonunion rates of ~14% in the tibia, fibula, and the femur are quite 
significant in light of the economic burden of the complication. In a 2014 review by Hak 
et al, the cost of treatment of one established long bone nonunion was stated to be 11,333 
United States dollars in the United States, 11,800 Canadian dollars in Canada, and 29,204 
British pounds in the United Kingdom. These high overall costs are largely due the 
accumulation of indirect costs such as productivity loss as a result of the complicated and 
lengthy healing course associated with fracture nonunion.48 
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In this review, the complication of fracture nonunion will be comprehensively described, 
beginning with an overview of current classification systems and a note on ambiguity in 
defining nonunion that has created variability in diagnosis. Following this introduction, 
the etiology of nonunion will be covered from micro to macro levels; current 
understandings of molecular pathology will be complemented by a discussion of well-
established clinical risk factors and comorbidities. Separate sections of this review will 
then be dedicated to current diagnostic techniques and treatment modalities employed 
clinically. The final section of this review will be forward looking with a discussion of 
future advancements, specifically in the area of diagnostics and new therapeutic 
approaches.  
 
Types of Nonunion 
Nonunions have traditionally been classified into two broad groups based on the 
biological viability of the bone fragments at the fracture site, as established in the late 
1970’s by Weber and Cech.50 The first of these classifications is characterized by a 
fracture site that has retained its biological potential, and thus is appropriately named 
hypertrophic. In these nonunions the bone fragments at the fracture site have an adequate 
blood supply and an observable callus. The maintenance of vascularity and the formation 
of callus tissues accompanying a failure in healing has primarily been associated with a 
mechanical failure in fixation caused by inadequate stability or premature weight 
bearing.50 Hypertrophic nonunion can be further subdivided radiographically into 
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elephant’s foot, horse’s hoof, or oligotrophic. These subdivisions descriptively defining a 
scale of radiographic presence of callus formation respectively diminishing from most to 
least.  Radiographically, oligotrophic nonunions appear very similar to atrophic 
nonunions, the other broad classification of nonunion, as reviewed below.  Oligotrophic 
nonunion however has been generally distinguished from atrophic nonunion based on a 
bone scan demonstration of vascularity.50 Figure 1 below demonstrates an example of 
hypertrophic nonunion. 
 
The second broad classification of nonunion is atrophic.  These nonunions are 
characterized by a hypo-vascular fracture site without any apparent callus tissue 
formation and have been defined as biologically insufficient. Atrophic nonunions are 
diagnosed radiographically by a lack of callus formation at the fracture site with an 
accompanying ischemic or cold bone scan.83   It is important to note that the 
characterization of atrophic nonunion as avascular is a more historical one, and recent 
literature has demonstrated vascularity is in fact present in some atrophic nonunions.79 
Atrophic nonunion can definitively be demonstrated not to arise as a result of mechanical 
fixation failure, in contrast to most hypertrophic non-unions. Instead, atrophic non-union 
is more likely to occur because of inadequate biological activity at the fracture site, 
possibly because of systemic comorbidities such as smoking and/or diabetes.50 Figure 2 
below demonstrates an example of an atrophic nonunion. 
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Beyond the atrophic vs. hypertrophic classification system, other radiographically and 
histologically distinguishable types of nonunion have been described.  One such 
classification is nonunions that have gone on to become a pseudoarthrosis, or “false 
joint”, in which the fracture gap has been filled with non-bony connective tissue. Such 
nonunions are considered either lax or stiff based on the type/composition of connective 
tissue and its accompanying mechanical stability. Those described as stiff nonunions 
have a fibrocartilage filler appearing radiographically as hypertrophic nonunions with 
appreciable callus formation and bony contact. Conversely, lax nonunions, also called 
synovial pseudoarthroses, are characterized by a filler of amorphous fibrous tissue 
appearing radiographically as atrophic nonunions with little callus formation and bony 
contact. Of note, Ilizarov described a third, middling classification on the gradation from 
stiff to lax, termed slack, considered to have hypertrophic qualities radiographically and a 
jog of movement.1 
 
One further classification of nonunions is made based on the presence/absence of 
infection, termed aseptic vs septic. Septic nonunions are radiographically determined 
nonunions accompanied by conventional clinical markers of infection i.e. presence of 
purulent wound discharge and/or necrotic bone and soft tissue. The diagnosis of a septic 
nonunion radically changes treatment modalities and therefore is a critical diagnosis for 
the clinician to make.1 Aseptic nonunions are simply nonunions that are not complicated 
by such infection. 
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Figure 1: Hypertrophic Nonunion of a Distal Third Tibial Shaft Fracture: 
This figure displays three radiographs (farthest left and farthest right are anteroposterior views, 
middle is a medial view) of a right distal third tibial shaft fracture 2 years after injury that has 
progressed to a hypertrophic nonunion. The initial treatment involved external fixation 
followed by plaster cast immobilization for several months. Callus formation is noted although 
the fracture is clearly in varus malalignment, indicating lack of mechanical stability as the 
likely culprit for progression to nonunion. Reestablishing mechanical stability in this patient 
will likely resolve the nonunion (Adapted from Harwood et al 2015). 
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Figure 2: Atrophic Nonunion of an Intertrochanteric Femur Fracture: 
This figure displays the results of two imaging studies (left is anteroposterior radiograph, right 
is a coronal computed tomography (CT) scan) of a left intertrochanteric femur fracture fixed 
with a trochanteric fixation nail and cerclage wiring.  These imaging studies were taken 9 
months following initial injury and fixation when the patient re-presented with pain and 
inability to bear weight on the left lower extremity. The absence of any callus between fracture 
fragments on radiograph and CT review indicates a lack of biologic activity and sclerosis, 
signaling atrophic nonunion. Treatment for this patient will involve re-stabilization of the 
fracture site likely through removal of the trochanteric fixation nail and application of a blade 
plate, as well as biologic stimulation including bone grafting. (Adapted from Harwood et al 
2015). 
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Delayed Union vs. Nonunion 
Currently, the definitions of nonunion and delayed union contain considerable overlap.  
Delayed union is considered to be a “fracture in which healing has not occurred in the 
expected time and the outcome remains uncertain.”  Nonunions are defined as “a 
symptomatic fracture with no potential to heal without intervention”.50 Such overlap has 
made it clinically difficult to determine when a delayed union has progressed to a 
nonunion, leading to subjective diagnoses in practice. Such subjectivity was assessed by 
Bhandari et al in 2002, who conducted a cross-sectional survey of 577 orthopaedic 
surgeons finding that surgeon definition of delayed union and nonunion ranged from 1 to 
8 months and 2 to 12 months respectively.8 Such results indicate a clear lack of consensus 
and fairly significant diagnostic variability.  
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CURRENT ETIOLOGICAL UNDERSTANDING  
 
A fracture’s progression to nonunion is still a largely unexplained, multifactorial 
processes involving combinations of dysregulation in molecular, cellular, structural and 
mechanical processes. Much research has been conducted into exactly which factors at 
each of these levels plays a role in disrupting the healing process, and many have been 
identified that will be discussed below. Figure 3 below represents a diagrammatic 
overview of such factors.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Molecular Factors Influencing the Development of Fracture Nonunion: 
This figure displays diagrammatically the multitude of factors that can contribute to the 
pathogenesis of fracture nonunion. In blue are depicted potential cytokinetic influences; 
in red are depicted potential genetic influencers. The yellow arrow on the top right 
depicts the influence that environmental factors such as smoking or systemic illness have 
on fracture nonunion. (Adapted from Ding et al 2018) 
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The Role of Cytokines 
Cytokines play a key role in regulating each of the four phases of fracture healing: the 
inflammatory phase, cartilage formation and mineralization phase, cartilage resorption 
phase, and remodeling phase. These important cytokines have been grouped into three 
categories by Gerstenfeld et al, who in 2003 described the process of fracture healing as a 
modified version of embryological skeletal development.44 Given their importance to 
directing the bone repair process, alterations in the signaling pathways of these cytokines 
can reasonably be connected to the development of nonunion and will be discussed. 
 
The first group defined by Gerstenfeld et al is proinflammatory cytokines, important 
molecules in initiating the fracture healing cascade and remodeling.44 Two notable 
proinflammatory cytokines that have been extensively studied for their role in fracture 
repair are tumor necrosis factor-alpha (TNF-alpha) and Interleukin-6 (IL-6). In a separate 
study, Gerstenfeld et al looked farther into the role of TNF-alpha, comparing wild-type 
and TNF-alpha receptor deficient mice, finding delayed cartilage resorption during 
endochondral bone formation in the receptor deficient group. From these results 
Gerstenfeld et al elucidated that TNF-alpha induces apoptosis in hypertrophic 
chondrocytes and recruits osteoclasts.44 In 2015 Chan et al showed that administering 
low-dose TNF-alpha in mice could augment fracture healing.15 These animal studies 
suggest that the dysregulation of TNF- alpha could contribute to development of 
nonunion, and provided a mechanistic association to nonunion that occurs in smokers and  
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diabetic patients.  As will be described below in the subsection “Other 
Comorbidities/Risk Factors”, smoking and diabetes have both demonstrated strong 
associations with nonunion. Nicotine, the primary active compound in tobacco, has been 
shown to inhibit TNF-alpha secretion through the cholinergic anti-inflammatory pathway 
while diabetes has been found to enhance TNF-alpha chondrocyte apoptosis and increase 
osteoclast presence, accelerating the loss of the cartilage therefore reducing eventual 
callus size.16,59,60 Recent work by Lim et al also found that diabetes markedly reduced 
angiogenesis in bone healing areas through a TNF-alpha mediated pathway.68 Despite 
these associations, it cannot be concluded that TNF-alpha is a sole actor in nonunion 
development or whose disruption is the primary mechanism between smoking or diabetes 
and nonunion; however, the results of these studies and others warrant further 
investigation with stronger levels of evidence into the association between TNF-alpha 
and nonunion. 
    
Another proinflammatory cytokine that has been extensively studied in relationship to 
fracture nonunion is IL-6. Yang et al found a decrease in callus strength and 
mineralization in IL-6 knockout mice.107 More recently, a mouse model study by Prystaz 
et al concluded that the classic IL-6 signaling response in the early posttraumatic phase 
was critical in regulating a balanced immune response and downstream processes leading 
to bone repair after fracture.86  Mechanistic molecular studies suggest that IL-6 and its 
receptor affect fracture healing through their regulation of mesenchymal stem cell (MSC) 
differentiation into osteoblasts.41 Recent clinical trials have more directly linked IL-6 to 
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nonunion development in humans.  Interestingly, Mathieu et al found in a prospective 
trial of atrophic nonunions that nonunion patients had higher serum IL-6 levels and lower 
serum IL-6 receptor levels than healthy patients.72 Continuing investigation is needed to 
formally establish a direct connection between nonunion and the IL-6 signaling pathway. 
 
The second group of regulatory factors that has been extensively examined during 
fracture repair is the transforming growth factor-beta (TGF-beta) superfamily. This 
family of factors includes bone morphogenetic proteins (BMPs), whose osteoinductive 
properties play a key role in regulating various stages of intramembranous and 
endochondral bone formation during fracture healing.44 Work by Niikura et al in a rat 
femur model showed that gene expression of BMP-2, 3, 3B, 4, 6, 7, and multiple BMP 
antagonists were significantly lower in nonunions at several time points when compared 
to normal healing fractures, suggesting that there is a downregulation of BMP family 
expression in nonunions.78 Studies in humans by Kwong et al and Fajardo et al also 
detected differences in levels of various BMPs and BMP inhibitors between nonunion 
and healing tissue.38,65 Disruption in the BMP signaling pathway may also represent one 
of the various mechanisms by which nonsteroidal anti-inflammatory drugs (NSAIDs) 
contribute to the pathogenesis of nonunion. In a study by Daluiski et al, osteoprogenitor 
cells treated with NSAIDs displayed a decreased response to BMP signaling, while a 
study by Li et al established that a BMP-2 induced chondrocyte regulatory pathway is 
cyclooxygenase-2 (COX-2) dependent and therefore susceptible to NSAID 
interference.27,66 The results of these investigations and others represent what could be a 
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critical mechanism behind the association between NSAID use and nonunion. The use of 
NSAIDs as a risk factor for nonunion development is described in more detail in the 
“Other Comorbidities/Risk Factors” subsection below.  
The third and final category of regulatory factors that has been extensively examined 
during fracture healing is the metalloproteinases and angiogenic factors.44 These two 
groups of proteins are considered together because of the concurrent nature of matrix 
degradation, regulated by matrix metalloproteinases (MMPs), and angiogenesis, 
regulated by vascular endothelial growth factor (VEGF), in endochondral bone 
formation.44 In studies by Kosaki et al and Colnot et al, MMP-13 and MMP-9 knockout 
mice respectively experienced deficiencies in cartilage resorption and therefor hindered 
bone remodeling.22,62 The important role of VEGF in fracture healing has been supported 
by two separate investigations by Chu et al. In the first study, Chu et al found increased 
expression of VEGF and its receptor in rabbits following a fracture with peak expression 
in the 3 day to 3 week window after injury.18 The subsequent work by Chu et al showed 
significantly lower blood flow to and impaired bone growth at the fracture site of rabbits 
given a VEGF polyclonal antibody. Interestingly in the same investigation, Chu et al 
found that administration of exogenous VEGF did not prove to be a stimulus of fracture 
healing over the control.19 An extensive literature review by Clarkin et al also supports 
the role of VEGF as a critical regulator of bone formation through its regulation of 
osteoblast activity and as a paracrine signaling molecule allowing communication 
between endothelial cells, osteoblasts, osteoclasts, and osteocytes.21 Conversely, 
Sarahrudi et al showed in humans that nonunion was in fact associated with higher serum 
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VEGF concentrations as compared to normal healing in patients over a 6-month 
observation period.89 This suggests that although VEGF is a critical cytokine for inducing 
angiogenesis in and around the fracture site, hypervascularization in the initial healing 
period may be harmful and contribute to nonunion.  
 
Genetic Factors 
The recent research boom into the influence of genetics on disease has extended to 
orthopaedics and nonunion, yielding intriguing results. Dimitrou et al broke ground in 
this topic in 2011 with a clinical study on single nucleotide polymorphisms (SNPs) in 
four genes involved in the BMP pathway. Results indicated that SNPs in two inhibitors of 
BMP, Noggin and Smad6, were associated with development of atrophic nonunion, 
however small sample sizes and no control for environmental factors limit the 
applicability of these results.33 Two following studies were able to control for such 
potential confounding variables. The first investigated 16 SNPs within five genes known 
to be associated with fracture healing, finding haplotypes in BMP-4 and fibroblast growth 
factor receptor-1 (FGFR-1) to be significantly associated with aseptic nonunion.46 The 
second investigation targeted SNPs in genes encoding various cytokines linked to 
fracture healing, establishing a significant link between a platelet derived growth factor 
(PDGF) haplotype and aseptic nonunion of the lower limb.109 Investigation into local 
gene expression at the fracture site itself has also identified 8 genes linked to the 
disruption of the structure, function, and environment of cells involved in the fracture 
healing process. These genes were all expressed at significantly higher quantities in 
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nonunion tissue as compared to fresh callus using complimentary deoxyribonucleic acid 
(cDNA) arrays.112 
 
Multiple recent animal studies have also given light to the role micro-ribonucleic acids 
(miRNAs) may have in nonunion development through their regulation of gene 
expression. Waki et al conducted two studies on the subject, first identifying five mRNAs 
expressed at high levels in nonunion bone tissue in a rat model.104 Waki et al expanded 
on their results just one year later, identifying five miRNAs upregulated in healthy rat 
bone tissue and therefore potentially protective against nonunion.105 Microarray analysis 
of miRNAs in aged female mice by He et al also identified 11 miRNAs significantly 
associated with impaired fracture healing based on a novel scoring system.51  
 
Osteogenic Cells and Vascularity 
The presence of osteogenic cells is critical to the bone healing process, recruited locally 
or delivered systemically in the aftermath of a fracture. In the progression to nonunion, it 
is reasonable to believe that these osteogenic cells are either largely absent or non-
functional in the healing process. Systemic illness, local infection, and open fractures are 
all factors that can compromise the health of osteogenic cells and limit their effectiveness 
in healing.50 Stripping of the periosteum, a fibrous membrane encasing most bones, can 
also contribute to impaired fracture healing by affecting the local availability and health 
of MSCs, multi-potent stem cells that can act as an osteoprogenitor and differentiate into 
osteogenic cells.50  The presence of MSCs in the periosteum has been corroborated by 
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multiple investigations and is therefore well established.3,30,77 One such convincing 
investigation by De Bari et al demonstrated the presence of cells expressing markers of 
MSCs in multiple samples of human proximal tibia periosteum that later differentiated in 
vivo and in vitro into various MSC lineages under specific conditions.30 Further 
investigation into periosteum-derived MSCs, such as by Zhang et al in a murine bone 
segmental defect model, directly supports their capability as an osteoprogenitor and role 
in bone repair.110 Taking into account the presence of such MSCs in the periosteum and 
their role in osteogenesis, it is clear how stripping can impact the availability of 
osteogenic cells at the fracture site and therefor negatively affect healing. 
 
Sufficient blood supply to the fracture site is also critical, ensuring the availability of 
non-local osteogenic cells, signaling molecules, and substrate necessary for bone healing. 
Impairments in vascularity and thus blood flow can lead to bone necrosis and affect the 
osteoconductive scaffold, effects that will very likely progress to nonunion. Work by Lu 
et al in a mouse model validated this idea, demonstrating that fracture site ischemia was 
significantly associated with decreased bone formation.71 Even more significantly, it has 
also been found that damage to one or more important veins in the lower limb following 
trauma results in a threefold increase in nonunion incidence.32 Such disruptions to 
vascularity can occur as a result of periosteal stripping as has been supported in an 
investigation in sheep by Kowalski et al, and/or destruction of the soft tissue envelope as 
occurs in higher grade open fractures.63 Less invasive implants including intramedullary 
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nails and plates can also disrupt bone vascularity despite their best attempts to preserve 
the native fracture biology.50 
 
The Mechanical Environment and Bony Contact 
The ability for a fracture to unite is also dependent on its mechanical environment, one 
the treating orthopaedic surgeon hopes to optimize. Creating such an optimal healing 
environment however is difficult, as both inadequate and excessive movement at the 
fracture site can create a failure of union. Inadequate fracture stability from conservative 
management or poor fixation is associated with hypertrophic nonunion, supported by a 
sheep model investigation by Epari et al as well as work by Lienau et al demonstrating 
early callus formation and quicker fracture union in adequately stabilized fractures.37,67 
However, excessive mechanical stabilization by fixation methods and an inadequate 
reduction can combine to limit boney stimulus required for fracture bridging and 
therefore nonunion.50 Such bone on bone contact absent in an inadequate reduction is 
critical for fracture healing, making large fracture gaps a notable risk factor for nonunion 
development. Such bony defects are under low strain and therefore do not promote 
osteoblastic activity, with animal studies demonstrating cortical defects between 1 and 
2mm to be the maximum that can be bridged with gaps greater than 2mm failing to 
achieve union.20,82 It should also be noted that the periosteum provides an additional 
source of mechanical stability for bone. In an investigation in rat femurs by 
Yiannakopoulos et al, periosteum-stripped bone showed significantly lower strength, 
stiffness, energy absorption, and deflection in a destructive three-point-bending test when 
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compared to periosteum-covered bone.108 This decreased lack of rigidity associated with 
periosteum-stripped bone presents another way in which stripping can affect healing and 
potentially contribute to the development of nonunion.  
 
Clinical Comorbidities/Risk Factors 
Although much remains to be discovered regarding the molecular pathogenesis of 
nonunion, multiple environmental, systemic, and injury related risk factors have been 
identified and validated in the literature. Beginning with comorbidities associated with 
nonunion, diabetic patients are more likely to experience impaired fracture healing for a 
multitude of associated reasons. First, the peripheral vasculopathy and neuropathy 
associated with diabetes have both been found to be significantly associated with bone 
healing complications, while low insulin production has also been found to cause reduced 
collagen production in osteoblasts in a rat model, likely impacting bone synthesis 
following fracture.94,97 Hemoglobin A1c (HbA1c) levels in diabetic patients >7% have 
also demonstrated a significant association with impaired fracture healing.94 Lastly, the 
anti-osteogenic effects of some diabetic drugs have also been linked to fracture healing 
impairment.95 Of note, obesity has also been linked to unfavorable outcomes in fracture 
healing as described by Sabharwal et al.88 One important pathology to note that is not 
associated with nonunion in osteoporosis. The absence of association was demonstrated 
by Van Wunnik et al in 2011, asserting that although osteoporosis was associated with a 
higher incidence of fracture, it did not in fact influence the occurrence of nonunion.101 
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Environmental factors affecting fracture healing and therefor contributing to the 
development of nonunion include smoking and the use of certain medications. A direct 
link between smoking and nonunion was established by Hernigou et al, while an 
understanding of nicotine’s vasoconstrictive effect and inhibition of TNF-alpha as well as 
carbon monoxide’s binding properties to hemoglobin and resulting tissue hypoxia give 
pathophysiological insight into the association.4,16,53 The idea that alcohol in excessive 
doses in the post-trauma period contributes to nonunion development is also supported in 
the literature by two animal studies.14,36 Multiple medications have also demonstrated 
significant association with nonunion. Pountos et al identified NSAIDs, some antibiotics, 
anticoagulants, and chemotherapeutics to all have an inhibitory effect on fracture healing 
due to their impairments of various osteogenic cells and neovasculogenesis.84 
Particularly, the link between NSAIDs and impaired fracture healing has been a major 
area of research. One of the first notable correlations between NSAIDs and nonunions 
was made by Giannoudis et al, finding that in their series of femoral shaft fractures, 70% 
of those that went on to nonunion were in patients who had taken NSAIDs.45 
Additionally, NSAIDs that act specifically through their inhibition of COX-2, an enzyme 
critical for the induction of osteoblasts after fracture, were found to impair fracture 
healing more than non-specific NSAIDs.42,103 This retrospective series and others as well 
as elucidation of a biochemical mechanism seems to establish a connection between 
NSAIDs and a failure of union; however, in vivo studies have not supported the 
connection.64 Further, in a time in which the opioid epidemic continues to present a major 
health crisis, further investigation must be done before excluding the use of NSAIDs in 
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pain regimentation for the orthopaedic patient population. A large multi-center clinical 
trial is currently underway further investigating this question, the results of which will 
offer the highest level of evidence to date regarding the association between NSAIDs and 
nonunion.13  
 
Various injury related factors have also been found to be associated with nonunion. High 
energy trauma typically results in more complex fractures complicated by soft tissue 
compromise.11 Such compromise can lead to inadequate blood flow to the fracture site 
and the associated consequences related to nonunion development as discussed in the 
subsection on vascularity above. Open injuries have also been found to experience 
delayed healing as compared to closed fractures.24 Fracture location on the bone itself is 
also of significance regarding fracture healing. Metaphyseal bone enjoys greater 
circulation and faster cortical bone resorption during healing as compared to diaphyseal 
bone, making diaphyseal fractures more at risk for nonunion.24,99 Comminuted fractures, 
transverse type fractures, and fractures with long butterfly segments have all also been 
found to be associated with healing impairment.12,40 Court-Brown et al have also 
demonstrated that fractures with accompanying compartment syndrome experienced a 
significant delay in fracture union.25 Lastly, deep infection at the fracture site can be 
linked to nonunion development through its causation of necrotic bone, osteolysis, and 
detrimental interposition of necrotic soft tissue between bone fragments.11   
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CURRENT DIAGNOSTIC TECHNIQUES 
 
Patient History and Examination 
Diagnosis of nonunion begins in the examination room via careful consideration of 
relevant patient history and current level of function. Incessant pain at the fracture site 
will be the first, most obvious sign of delayed healing or nonunion. Assessing the 
patient’s current functional levels will also give insight into the mechanical demands 
being placed on the fracture and its fixation. Prescribed weight-bearing status and 
compliance is critical to the clinical assessment of nonunion as delayed weight-bearing 
has been found to be associated with nonunion.56 A recent survey of more than 300 
orthopaedic surgeons found lack of weight-bearing ability to be the most important 
clinical criterion for diagnosis of nonunion, followed by fracture pain and then weight-
bearing status.7  A consideration of risk factors for nonunion include if the initial fracture 
was open, if there was compartment syndrome, and/or if the patient displayed any signs 
of infection during healing. Such considerations are both important in the ongoing 
assessments of the progression of healing and in the determination of a nonunion 
diagnosis. When considering the diagnosis for nonunion, evaluation of movement at the 
fracture site, neurovascular status, lengthening or shortening of the fracture segment, as 
well as signs of infection are all important in assessing the likelihood of fracture 
nonunion.50 
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Imaging Evaluation 
Imaging studies remain a crucial tool in diagnosing nonunion, supplementing the 
aforementioned thorough clinical evaluation.  Plain radiographs remain the most 
commonplace imaging study and can be moderately useful in assessing signs of 
progressive union, bone quality, implant status, and potential malalignment. Increasing 
displacement and angulation at the fracture site as well as implant loosening or failure are 
all red flags for potential current or impending nonunion when performing a radiographic 
analysis.50 Radiographic determination of nonunion can prove difficult however, as 
multiple studies cite their poor reliability in determining the stage of union.28,49 This 
finding has been met with attempts to standardize radiographic criteria to assess union, 
giving way to radiographic union score for tibia (RUST) and radiographic union score for 
hip (RUSH).  
 
The RUST score uses anteroposterior and lateral radiographs of the tibia to assess callus 
formation and fracture line visibility at anterior, posterior, lateral, and medial cortices. A 
score is given to each of the four cortices from 1 to 3, where a 1 denotes absent callus and 
a visible fracture line, a 2 denotes present callus but still a visible fracture line, and a 3 
denotes present callus and no visible fracture line. Thus, the minimum RUST score that 
can be achieved is a 4, while the maximum is a 12. Figure 4 below demonstrates a right 
distal third tibial shaft fracture in which the RUST score has been applied. Agreement 
among seven expert reviewers using the score was then assessed using 45 sets of 
anteroposterior and lateral radiographs, to which interobserver agreement was profound 
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at both initial assessment and another nine weeks later.106 Of note, a more recent 
modified RUST (mRUST) score has been developed showing slightly higher 
interobserver agreement. This modified score still utilizes evaluation of anterior, 
posterior, lateral, and medial cortices via anteroposterior and lateral radiographs, however 
the intermediary “present callus” score of 2 is subdivided into “callus present” and 
“bridging callus” categories. This subdivision was introduced in order to better stage the 
progression of fracture healing since complete remodeling and loss of fracture line, i.e. 
the top score, occurs late. The subdivision of the intermediate score allows for 
quantitative distinction between the presence of callus, given a score of 2, and bridging 
callus, given a score of 3, clinically different healing stages previously grouped together 
and given an identical score of 2 under the traditional RUST. A completely remodeled 
fracture line receives a score of 4 under the mRUST criteria, while no callus present is 
still given a score of 1. This means the minimum score a fracture can achieve under 
mRUST is 4, with a maximum of 16.69 Importantly, both RUST and mRUST have 
displayed strong correlations in animal studies with biomechanical parameters, bone 
mineral density and healing time.23,39 In a recent study in a sheep osteotomy model by 
Litrenta et al, a RUST score of 10 and mRUST of 14 was determined to be excellent 
union by all surveyed surgeons, while a RUST score of 10.4 and mRUST of 14.2 was 
labeled united by biomechanical testing, demonstrating excellent surgeon judgement and 
testing agreement. Interestingly, the mRUST also displayed a higher interclass correlation 
coefficient than the traditional RUST in this investigation.70 
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The RUSH score works in much the same way as the RUST score, however in the RUSH 
score cortical bridging and fracture line visibility are given separate scores rather than a 
combined score. Trabecular consolidation and trabecular fracture line presence are also 
assessed and scored and included in the overall RUSH score calculation. The scale 
remains a simple 1 to 3; for cortical bridging, a 1 denotes no bridging, a 2 denotes some 
bridging, and a 3 denotes complete bridging. For fracture line visibility, a 1 denotes full 
fracture line visibility, a 2 denotes some evidence of a fracture line, and a 3 denotes no 
visible fracture line. As for the additional categories to be assessed, for trabecular 
consolidation a 1 denotes no consolidation, a 2 denotes some consolidation, and a 3 
denotes complete consolidation. Evidence of trabecular fracture line uses the same 1 to 3 
scale as prior fracture line visibility assessment categories. Anteroposterior and lateral 
films of the hip are used to assess anterior, posterior, lateral, and medial cortices. Two 
scores from 1 to 3 given to each of the four cortices with additional scoring of trabecular 
consolidation and fracture line establish a minimum RUSH score of 10 and maximum of 
30.17 Figure 5 below demonstrates a right intertrochanteric femur fracture in which the 
RUSH score has been applied. The score was validated through two investigations by 
Bhandari et al, both finding strong inter-observer agreement and therefore reliability.5,6 
However, despite strong interobserver agreement and promise among the RUST, 
mRUST, and RUSH scores, direct applicability in predicting and/or diagnosing nonunion 
remains limited. 
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The use of CT scanning has also proved to be a valuable, and often more reliable, 
diagnostic imaging study in assessing nonunion.75 Work by Bhattacharyya et al 
demonstrated that CT scans have a 100% sensitivity for detecting nonunion, although 
only a 62% specificity.9 In a separate study by Schnarkowski et al in tibial shaft fractures 
an increase of 50% callus formation determined by CT review after 12 weeks was 
associated with fracture stability of 100% with specificity of 83%.91 Unfortunately, the 
use of CT scans in diagnosing nonunion is limited by artifact created by implants 
adjacent to the fracture site.75  
 
Lastly, ultrasound as a diagnostic tool for assessing nonunion has been documented. 
Although ultrasound is incapable of penetrating cortical bone, Craig et al demonstrated 
its ability to detect developing callus before such callus is visualized radiographically.26 
Further work by Moed et al demonstrated that their ultrasound findings in eight canine 
tibias had a 100% correlation with the presence of hard fracture callus biopsy tissue.74 
Although currently limited in its use in practice, improvements to ultrasound technology 
will likely increase its translation as a sensitive diagnostic tool for nonunion.  
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Figure 4: Calculation of the RUST Score in a Distal Third Tibial Shaft Fracture: 
This figure depicts two radiographs of a right distal third tibial shaft fracture three months after 
treatment with a reamed intramedullary nail. In accordance with established RUST criteria, the 
two radiographs to be evaluated are a lateral (left) and anteroposterior (right) view. Four scores 
have appropriately been applied to each of the four cortices in question. The anterior cortex, 
visible on the lateral view, has been given a RUST score of 2 since it has both visible callus and 
a visible fracture line. The posterior cortex, also visible on the lateral view, has also been 
assigned a RUST score of 2 for having both visible callus and a visible fracture line. The lateral 
cortex, visible on the anteroposterior view, has also been assigned a RUST score of 2 for having 
both visible callus and a visible fracture line. Lastly, the medial cortex, also visible on the 
anteroposterior view, has been assigned a RUST score of 1 for having no visible callus and a 
visible fracture line. The overall RUST score of this fracture at this stage in healing is 7 out of a 
possible 12. (Morshed et al 2014) 
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Figure 5: Calculation of the RUSH Score in an Intertrochanteric Femur Fracture: 
This figure depicts two radiographs of a right intertrochanteric femur fracture six months after 
treatment with a dynamic hip screw. In accordance with established RUSH criteria, the two 
radiographs to be evaluated are a lateral (left) and anteroposterior (right) view. Eight scores 
have been applied to the four cortices plus two additional scores. The anterior cortex, visible 
on the lateral view, has been given a cortical bridging RUSH score of 3 for complete cortical 
bridging, and a fracture line RUSH score of 2 since there is some evidence of a fracture line. 
The posterior cortex, also visible on the lateral view, has been given a cortical bridging 
RUSH score of 3 for complete cortical bridging, and a fracture line RUSH score of 2 since 
there is some evidence of a fracture line. The lateral cortex, visible on the anteroposterior 
view, has been given a cortical bridging RUSH score of 2 for some cortical bridging, and a 
fracture line RUSH score of 1 since the fracture line is fully visible. The medial cortex, also 
visible on the anteroposterior view, has been given a cortical bridging RUSH score of 3 for 
complete cortical bridging, and a fracture line RUSH score of 2 since there is some evidence 
of a fracture line. Lastly, some trabecular consolidation warrants a RUSH score of 2, as does 
some evidence of a trabecular fracture line. The overall RUSH score of this fracture at this 
stage in healing is 22 out of a possible 30 points. (Morshed et al 2014) 
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Blood Tests 
At the moment no specific marker in the blood for nonunion has been identified, however 
blood tests remain a mainstay when assembling the clinical picture of a potential non-
healing fracture. C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and 
white blood cell (WBC) count, tests that give insight into the inflammatory state of the 
body, might provide evidence of an impaired repair process in a patient; however, these 
tests remain more useful for identifying infection.75 The use of more specific serologic 
markers is a topic of ongoing research, and one that will be discussed in the “Future 
Diagnostics” section of this review. 
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CURRENT THERAPEUTIC APPROACHES 
 
Once a diagnosis of nonunion has been made, there are multiple treatment options that 
can be employed. These treatment options include non-operative and operative 
modalities, bone stimulation, and pharmacologic therapies. The first major treatment 
decision that must be made is whether to pursue operative or non-operative management 
of the fracture nonunion. If the surgeon decides against surgical intervention, then 
treatment will involve some combination of splinting to regain mechanical stability, 
physical therapy, analgesia, and antibiotics.50 The use of antibiotics is especially critical 
if local infection is suspected as it is likely a contributing factor to the impaired bone 
healing. Elimination of infection may allow for bone healing to reinitiate without further 
intervention. Also, if it is determined that the patient is smoking or using NSAIDs 
regularly, a recommendation to cease these activities is made as both these factors have 
been demonstrated to be associated with impaired fracture healing.45,53 
Although conservative management provides multiple avenues with which to improve 
patient comfort as well as modify environmental and systemic factors potentially 
contributing to impaired bone healing, it is more often that once a determination of 
nonunion has been made a surgical treatment is pursued. Surgical intervention is often 
indicated because it allows for placement of more robust internal or external fixation to 
aid in critical fracture site stability and/or apply local biologics such as bone graft to 
augment native bone growth and potentially unite large fracture gaps proven incapable of 
bridging.50 Such techniques will be described in further detail below.  
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Surgical Modalities 
In their review of current treatment approaches for nonunion, Harwood et al described 
four goals of surgical treatment for nonunion: restore limb alignment, obtain appropriate 
stability, enhance fracture site biology, and eradicate infection.50 It is essential that each 
of these goals be considered and addressed in treatment. In order to address and hopefully 
improve both limb alignment and appropriate stability, initial fracture fixation must come 
under question. If initial fixation hardware exists, the fixation may be augmented or 
revised to provide for a better mechanical environment conducive to fracture healing. A 
common approach is to remove and replace the initial hardware with a different 
combination of implants and/or external hardware in order to achieve a better reduction 
and ensure improved stability. Optimization of the mechanical environment also involves 
correcting limb alignment, especially in cases where the fracture instability from 
nonunion has caused the limb to fail into varus or valgus malalignment. Restoration of 
alignment will restore the mechanical axis of the limb and reoptimize on-axis force 
transmission that will improve function and protect implants.50 Optimization of the 
mechanical environment through effective reduction and implant placement may also 
serve to restore native limb alignment; however, this is not always the case indicating the 
need for an osteotomy, or bone removal, procedure. In this procedure an angulated wedge 
or segment is removed directly from the malaligned bone or in the bone adjacent, such as 
in the fibula to correct tibial alignment.1 In the case of hypertrophic nonunion, 
accomplishing optimization of the mechanical environment and proper limb alignment 
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should be adequate in initiating effective healing that will correct the nonunion. An 
optimized mechanical environment is also crucial to the treatment of atrophic nonunion, 
however this may already be present given the underlying cause of atrophic nonunion to 
be non-mechanical.  
 
In some complicated cases of nonunion, amputation may become the indicated surgical 
procedure. Complex recalcitrant cases, when infection is present, and when tissue and 
function distal to the nonunion is unsalvageable makes removal of at least part of the 
affected limb the most prudent option.50 However, not all complicated septic nonunions 
progress to requiring an amputation.  One surgical technique that has provided a broadly 
used alternative to amputation in these cases as well as in stiff, aseptic hypertrophic 
nonunions is distraction osteogenesis with an Ilizarov external frame. If it is a septic 
nonunion, this technique first involves debridement of infected tissue including bone at 
the nonunion sight, often creating or exacerbating cortical defects that are usually 
exceptionally difficult to recover. Then, an Ilizarov external frame is applied that 
stabilizes the bone segments on either side of the nonunion.  The segments of bone 
themselves are attached to the external frame through percutaneous olive wires 
perpendicular to the limb axis. These wires are often coated with hydroxyapatite as this 
has been shown to support osseointegration and greater torsional strength.  Between each 
segment of bone is the hinge of the frame that overlays the nonunion site itself, that of 
which will be manipulated to carry out the distraction.1 The distraction itself is the key, 
which Ilizarov demonstrated in a landmark paper promotes tissue such as bone to revert 
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to an undifferentiated state that then matures into new structures.58 Distraction does not 
usually begin until after a latency period, usually with a phase of compression to excite 
an inflammatory response, and then proceeds at a constant rate usually around 1mm per 
day dependent on the bone in question and various patient factors.90 Overall, the frame 
provides a magnificent way of providing mechanical stability as well as stimulation 
shown to promote bone synthesis in some of the most complicated nonunion cases. 
Figure 6 below is picture of an an Ilizarov external frame side by side with a radiographic 
view of the applied distraction in the tibia.  
 
 As indicated by Harwood et al, optimizing the biological environment is also an 
important surgical goal of the orthopaedic surgeon. Direct access to the surgical site 
allows the surgeon to remove non-vital or inert tissue potentially impeding 
communication between fracture fragments. This is especially critical if the non-vital 
tissue is necrotic or infected, as eradicating infection is another crucial surgical goal in 
nonunion treatment as described by Harwood et al. Eradicating such infection plays a role 
in optimizing the biological environment and ensures that the formation of healthy bone 
will not be impeded by a harmful microbiological presence.50 Direct access to the 
surgical site also allows the surgeon to implant biological adjuncts, the most notable 
being autologous bone graft. Autologous bone graft, also known as autograft, is most 
usually harvested from the iliac crest because it has proven to be an osteogenic, 
osteoinductive, and osteoconductive source that has been shown to contain precursor 
cells.92 Therefore, placement of autograft at the site of nonunion in the fracture gap itself 
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provides a biologically active scaffold that should stimulate bridging. The use of iliac 
crest autograft has come under question recently, and the efficacy of potential 
replacements will be discussed in the “Future Treatment Modalities” subsection of the 
“Future Advancements” section.  
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Figure 6: Application of an Ilizarov External Fixator to the Tibia for the purpose of 
Distraction Osteogenesis: 
This figure depicts two views of an Ilizarov external fixator that has been applied to the tibia as 
treatment for a stiff hypertrophic nonunion. On the left is a picture of the “classic” Ilizarov 
frame utilized in this case, shown here as a four-ring construct that creates two stable columns, 
one proximal and one distal to the site of nonunion. Small diameter olive wires can be seen 
entering the skin (that insert into the bone, although not visible here) from each of the four 
rings perpendicular to the axis of the tibia. A Gough Stewart hinge created between the two 
columns overlays the nonunion itself and was distracted at a max rate of 0.75mm per day 
following a two-week compression period. On the right is an anteroposterior radiograph of the 
same tibia after some distraction of the nonunion site has occurred. The fracture gap displays 
notable callus formation, a result of the distraction osteogenesis pathway stimulated here and 
first described by Ilizarov. (Atkins et al 2007) 
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Pharmacologic Therapy 
Based on the results of multiple studies exogenous BMPs are currently in use as a 
therapeutic approach to nonunion. BMP-2 and BMP-7 are the two that are currently 
commercially available, although the results of two recent trials investigating each when 
used in conjunction with bone grafting only supports the efficacy of BMP-7.80,98 An even 
more recent trial investigating the efficacy of both BMP-2 and 7 however concluded that 
neither proved beneficial in aiding the healing of forearm nonunion.102 This compounded 
with another recent trial finding the use of BMP-2 to be significantly associated with a 
higher complication rate in scaphoid nonunions calls the therapeutic use of BMPs into 
question.10  
 
Bone Stimulation 
In addition to traditional surgical techniques and more recent use of biologic 
pharmacotherapy, electrical bone growth stimulation is in use clinically as a way to 
promote healing in nonunion fractures. These stimulators come in many different 
varieties, categorized by their use of direct coupling, capacitive coupling, inductive 
coupling, and ultrasound stimulation. Currently, all 4 types are indicated for the treatment 
of nonunion, however a recent meta-analysis by Haglin et al found that only capacitive 
coupling stimulators and inductive coupling stimulators have Level-II or Level-III study 
evidence supporting their use. Of note, Haglin et al also found that no electrical 
stimulator of any kind has been proven effective for treatment of nonunion in a Level-I 
study. However, despite a paucity of large conclusive clinical trials, basic science and 
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smaller trials strongly support the efficacy of at least capacitive coupling and inductive 
coupling bone stimulators for use in nonunion treatment.47 Future trials investigating 
bone stimulation in nonunion specifically as well as cost effectiveness should be 
conducted.  
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FUTURE ADVANCEMENTS 
 
Future Diagnostic Tools 
Currently, diagnosing nonunion involves some combination of clinical evaluation, 
imaging review, and blood analysis, none of which provide conclusive proof of the 
complication and all of which rely on some form of subjective assessment. Thus, research 
in this area has aimed to reduce the influence of such subjectivity, hoping to identify 
more concrete tests that establish a defined and faithful diagnostic threshold by which to 
distinguish a fracture that will never heal without intervention from one that is simply 
delayed. As discussed above, finding a serologic marker or markers for nonunion should 
theoretically provide such objective evidence. Studies in both animals and humans have 
explored this frontier, seeking to identify serologic markers of bone formation, bone 
turnover, angiogenesis, and mineral metabolism, as well as compare the levels of such 
markers in an animal or human with a fracture undergoing normal healing from an animal 
or human suffering from impaired healing.57 One such promising marker identified by 
Komnenou et al is alkaline phosphatase, an enzyme shown to be elevated for long periods 
in a dog model with delayed union.61 Another serologic marker that has been identified is 
osteocalcin. Herrmann et al found that at 4 weeks post-operatively, osteocalcin levels in 
the delayed union group were significantly lower than that in the normal fracture healing 
group.54 Zimmermann et al and Henle et al have also investigated the prognostic value of 
TGF-Beta1 and matrix metalloproteinases respectively, finding significant differences in 
the levels of both in delayed union and normal fracture healing groups.52,111 VEGF has 
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been described as an important angiogenic growth factor in the fracture healing process, 
and Sarahrudi et al demonstrated differing serum VEGF concentrations between fracture 
nonunion and normal healing groups.89  Lastly, the use of circulating BMP levels has also 
been indicated as a potential marker for nonunion, although van Baardewijk et al found 
there was no significant difference in circulating BMP-2, 4, 6, or 7 levels between 
nonunion and normal fracture healing patients.100 Given aforementioned investigations 
into the difference in several BMP and BMP antagonist levels in nonunion versus healthy 
bone tissue, measures of BMP concentrations at the fracture site may however prove 
efficacious as a prognostic tool for nonunion detection.34 However despite the 
identification of these potential markers, Pountos et al and Hussein et al assert that 
research in this area is ultimately inconclusive due largely to small sample sizes and an 
inability to control for potential confounders in the investigations to date.57,85 
Nonetheless, there is good reason to believe that larger trials hopefully to be conducted in 
the near future with better controls and more sensitive testing would be effective in 
identifying such a serologic marker.  
 
With the identification of potential genetic influencers on nonunion progression comes 
the possibility of genetic screening as a future prognostic tool, a topic explored by 
Dimitrou et al. Here, the authors describe that screening for SNPs that have been linked 
to impaired fracture healing could provide a valuable tool that allows for earlier 
intervention and better outcomes in nonunion fractures. It is important to note that the 
reliability of such a prognostic tool is contingent upon stronger evidence than what 
  38 
currently exists in the literature linking certain SNPs to nonunion. The authors are also 
careful to note that at present, genetic screening for all fractures is not cost-effective; 
however, once more concrete evidence connecting certain SNPs to nonunion exists, 
screening for such genetic markers in patients displaying other signs of nonunion might 
prove to be an economic and valuable prognostic tool.33  
 
The importance of improving current diagnostics in addition to the development of 
futuristic techniques as a means of better nonunion detection cannot be understated. The 
RUST, mRUST and RUSH scores present validated and reliable assessment tools in 
healing progression, and simply need to be more strongly correlated with clinical 
outcomes in humans in order to be a more applicable. Although it has been shown that 
values of the mRUST score at three months can predict delayed union at follow up at 
around 6 months, a more well-defined threshold score at a specific time point that 
predicts nonunion would make the scoring systems infinitely more valuable.81 
Improvements to ultrasound and CT technology will also likely create more advanced 
imaging opportunities to supplement traditional radiographic review.  
 
Future Treatment Modalities 
As was discussed below, autograft from the iliac crest remains the gold standard in bone 
graft for use in nonunion local biologic stimulation.92 Despite its osteogenic properties, 
the use of such autograft from the iliac crest has come under question for its association 
with postoperative pain, immobility, and prolonged hospital stay in patients.50 This has 
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prompted research into other sources of autograft with less disruptive harvesting 
techniques, such as the reamer irrigator aspirator system. This system harvests autograft 
from the femoral canal instead of the pelvis and uses a percutaneous approach and 
suction technique rather than the traditional open harvesting technique. Results thus far 
point to lower donor site morbidity in addition to union rates comparable, and in some 
cases superior, to iliac crest autograft.29 Demineralized bone matrix has also been 
investigated as an alternative to autograft since it has displayed osteoconductive 
properties. Work by Hierholzer et al supports such bone matrix as a viable alternative 
through their study on its use in humeral nonunion, detecting similar union rates when 
compared to iliac crest bone graft with lower donor site morbidity.55 The use of harvested 
bone marrow aspirate as well as platelet-rich plasma injected at the fracture site has also 
gained traction as a bone healing stimulant and may be used in the near future as a less 
invasive approach to augment other more traditional forms of nonunion treatment.96 
Interestingly, in Europe a synthetic bioactive ceramic bone substitute has been developed 
and is even licensed for treatment. The ceramic is both antibacterial and osteoconductive 
and as it becomes incorporated into bone can provide a local defense mechanism to treat 
or thwart infection.35 The implementation of such a substitute could prove a valuable tool 
in septic nonunion or even as a prophylactic measure in aseptic ones.  
 
BMP is currently the only biological stimulant in use clinically to promote nonunion 
healing, however others appear to be on the horizon. Topical and systemic infusion of 
other bone healing associated cytokinetic compounds TGF-beta, VEGF, and PDGF have 
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all yielded at least some promising results in animal models prompting clinical trial 
testing potentially in the near future.3 The use of pharmacologic agents such as 
parathyroid hormone (PTH) and growth hormone (GH) as bone healing promoters has 
also gained traction. A recent review by Della Rocca et al summarizes progress that has 
been achieved in animal models associating PTH administration and bone healing and 
supports it as a good potential candidate for reducing rates of fracture nonunion.31 Animal 
studies, such as that conducted by Raschke et al in pigs, also suggest a supplemental role 
of GH in fracture healing.87  
 
Just as genetic testing presents a potentially valuable future diagnostic tool for nonunion, 
gene therapy presents a potential future treatment approach. A recent review by Shapiro 
et al demonstrates promising progress in this area, citing especially exciting progress in 
the use of exogenous miRNA to enhance bone regeneration in distraction osteogenesis 
models and critical-sized defects.93 Work by Murata et al also elucidates a potential 
therapeutic benefit to downregulation of miRNAs that inhibit the bone healing process as 
opposed to just upregulation of poor-bone healing ones.76 Work in this field has mostly 
been targeted at treatment of osteoporotic fractures, however could be investigated as a 
treatment for nonunion in the near future.93   
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FINAL CONCLUSIONS 
 
Nonunion remains a debilitating, puzzling, and expensive challenge for both the patient 
and treating orthopaedic surgeon. Assessment still remains largely subjective, despite 
best efforts to standardize definitions and diagnostic criteria. Extensive research into the 
molecular pathology of the complication has uncovered multiple potential mechanisms to 
explain the pathology of the disease including elucidation of the important role of various 
cytokines such as BMP and TNF-alpha and the effects of their disruption on the healing 
process. Although much still remains unknown mechanistically, the orthopaedic 
community has successfully identified multiple risk factors for development of nonunion. 
Discovery of the association of such risk factors as smoking and compartment syndrome 
with nonunion provides an important clinical tool for the physician in stratifying a 
patient’s risk for a complicated healing course as well as useful in aiding in nonunion 
diagnosis. Recognizing treatment factors associated with progression to nonunion such as 
inadequate stabilization and large cortical gaps also presents the treating orthopaedic 
surgeon with modifiable risk factors with which to experiment and potentially improve 
nonunion incidence in their practice.   
 
It is clear the future of nonunion diagnosis and treatment lies largely with the 
identification of serological markers and genetics.  Promising blood markers such as 
alkaline phosphatase as well as multiple BMP isoforms are currently under review and 
should in the near future augment traditional diagnostic tools of clinical evaluation and 
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imaging review. Additionally, further research into the correlations between validated 
imaging scores such as mRUST and the clinical picture will hopefully make these scores 
more translatable as a diagnostic tool. Improved treatment options will likely first come 
in the form of autograft with harvesting that does not compromise the patient’s health, as 
well as locally applied cytokinetic supplements. On the more distant horizon is a 
bacteriocidal ceramic compound that could prove incredibly valuable in thwarting 
infection directly at the site of nonunion. The most distant future diagnostic and 
therapeutic approaches for nonunion lie with an ever-expanding genetic understanding, 
an understanding that has the potential to provide significant breakthroughs. The use of 
genetic screening to identify patients most susceptible for nonunion would be a critical 
prognostic tool that would allow for more immediate intervention, while genetic therapy 
might be able to provide the most direct mechanism by which to alter fracture healing 
biomechanics. Nonetheless the technology is still in development, representing an 
exciting future advancement that may one day revolutionize treatment for this frustrating 
and tragic complication.  
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